BRAF and colorectal carcinoma: In patients with MLH1-deficient CRC, direct testing of MLH1 promoter hypermethylation and/or BRAF V600E mutational analysis, may be a cost-effective means of identifying patients with sporadic tumors for whom germline genetic testing is not indicated.